“This landmark study shows once and for all that convalescent plasma is an important countermeasure early in a pandemic when no other therapies are available.
It was an important finding that lays the foundation for the rapid response to future pandemics,” said Luis Ostrosky, MD, professor and director of the Division of Infectious Diseases at McGovern Medical School at UTHealth Houston.
“This trial, the largest of its kind, also showed that with proper funding and structure, researchers across the country were able to come together quickly in the middle of a global crisis to explore this therapeutic intervention.”
Results of the trial also showed that after the introduction of remdesivir and corticosteroids, efficacy dropped and by the end of the 11-month trial, there was no difference in outcome between plasma and placebo in patients at 14 and 28 days. However, patients on corticosteroids, but not remdesivir, appeared to benefit from convalescent plasma at day 14.
Because the patient characteristics, available treatments, and the virus, changed over time, subgroup analyses were done, which revealed the possible benefit for patients in the first quarter of the trial, a period from April to June 2020.
Participants in that first quarter were older, less severely ill, had a longer duration of symptoms, and received high-titer plasma. A shorter duration of symptoms is an indication of a more severe case of the viral infection.
“Convalescent plasma could be an important early treatment tool in places that don’t have access to monoclonal antibodies, corticosteroids, remdesivir, or other therapies,” said Bela Patel, MD, co-investigator, professor and director of the Division of Critical Care, and Graham Distinguished University Chair at McGovern Medical School.
“It should also be considered for patients who are immunosuppressed and those whose B cell function is compromised.”
Researchers also reported that, in addition to the introduction of corticosteroids and remdesivir, the decrease in efficacy over time may have been due to using convalescent plasma that originated from New York City before other viral variants emerged.
“It is vitally important to do research such as this during a pivotal public health crisis to determine what works and what doesn’t and use that information for future pandemics.
We are proud to be part of such a milestone clinical trial,” said David McPherson, MD, co-investigator for the trial, principal investigator of CCTS, chair of the Department of Internal Medicine at McGovern Medical School at UTHealth Houston, and James T. and Nancy B. Willerson Chair.
Source: Medindia
